Breaking News, Financial News

Financial Report: Akorn

Revenues up 19% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Akorn 4Q Revenues: $85.0 million (+19%) 4Q Earnings: $16.7 million (+89%) FY Revenues: $317.7 million (+24%) FY Earnings: $52.4 million (+48%) Comments: In the quarter, the company announced the acquisition of Hi-Tech Pharmacal, expanding its branded ophthalmic portfolio, filed 12 ANDAs and completed the development of an additional 11 ANDAs, and completed the acquisition of the U.S. rights to three branded ophthalmic products from Merck: AzaSite, COSOPT and COSOPT PF. The company’s overall...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters